{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:22:38Z","timestamp":1793744558088,"version":"4.6.1"},"reference-count":220,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222901"],"award-info":[{"award-number":["82222901"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272619"],"award-info":[{"award-number":["82272619"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103355"],"award-info":[{"award-number":["82103355"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","award":["CUHK 14117422"],"award-info":[{"award-number":["CUHK 14117422"]}],"id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","award":["14119524"],"award-info":[{"award-number":["14119524"]}],"id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","award":["14117123"],"award-info":[{"award-number":["14117123"]}],"id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.pharmr.2024.100018","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T17:01:01Z","timestamp":1736269261000},"page":"100018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Pharmacological treatment for metabolic dysfunction\u2013associated steatotic liver disease and related disorders: Current and emerging therapeutic options"],"prefix":"10.1016","volume":"77","author":[{"given":"Xiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry Cheuk-Hay","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmr.2024.100018_bib1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.chom.2018.05.003","article-title":"Gut microbiota regulation of tryptophan metabolism in health and disease","volume":"23","author":"Agus","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.pharmr.2024.100018_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A\u00a0prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib3","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2024.100018_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.2040-4603.2018.tb00008.x","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr Physiol"},{"key":"10.1016\/j.pharmr.2024.100018_bib5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrgastro.2013.182","article-title":"The genetics of NAFLD","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s40168-021-01125-7","article-title":"Commensal microbe-derived acetate suppresses NAFLD\/NASH development via hepatic FFAR2 signalling in mice","volume":"9","author":"Aoki","year":"2021","journal-title":"Microbiome"},{"key":"10.1016\/j.pharmr.2024.100018_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature12331","article-title":"Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota","volume":"500","author":"Atarashi","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2024.100018_bib11","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.30690","article-title":"Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial","volume":"70","author":"Bajaj","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib12","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.31609","article-title":"Identification of a metabolic, transcriptomic, and molecular signature of patatin-like phospholipase domain containing 3-mediated acceleration of steatohepatitis","volume":"73","author":"Banini","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/hep.29273","article-title":"The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation","volume":"66","author":"BasuRay","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib14","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2024.100018_bib15","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.3390\/ijms23084334","article-title":"The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome","volume":"23","author":"Bednarz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2024.100018_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non\u2013alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2024.100018_bib17","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pharmr.2024.100018_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002503","article-title":"Fecal transplants: what is being transferred?","volume":"14","author":"Bojanova","year":"2016","journal-title":"PLoS Biol"},{"key":"10.1016\/j.pharmr.2024.100018_bib20","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.pharmr.2024.100018_bib21","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1007\/s00125-016-4110-5","article-title":"Reduction in liver fat by dietary MUFA in type 2 diabetes is helped by enhanced hepatic fat oxidation","volume":"59","author":"Bozzetto","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2024.100018_bib22","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2337\/dc12-0033","article-title":"Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients","volume":"35","author":"Bozzetto","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2024.100018_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pharmr.2024.100018_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.20920","article-title":"Insulin resistance: a metabolic pathway to chronic liver disease","volume":"42","author":"Bugianesi","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib25","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2024.100018_bib26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","article-title":"Gut microbial metabolites in obesity, NAFLD and T2DM","volume":"15","author":"Canfora","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pharmr.2024.100018_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.gastro.2017.03.051","article-title":"Supplementation of diet With galacto-oligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals","volume":"153","author":"Canfora","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2024.100018_bib28","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/HEP.0000000000000474","article-title":"An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations","volume":"78","author":"Carr","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","article-title":"A\u00a0gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease","volume":"10","author":"Caussy","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2024.100018_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib31","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jfda.2018.12.011","article-title":"Next generation probiotics in disease amelioration","volume":"27","author":"Chang","year":"2019","journal-title":"J\u00a0Food Drug Anal"},{"key":"10.1016\/j.pharmr.2024.100018_bib32","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.3390\/ijms21155214","article-title":"Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharmr.2024.100018_bib33","article-title":"Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma","volume":"10","author":"Chen","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.pharmr.2024.100018_bib34","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/jgh.15027","article-title":"Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non-alcoholic fatty liver disease","volume":"35","author":"Chen","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib35","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41591-023-02553-8","article-title":"Interaction between estrogen receptor-\u03b1 and PNPLA3\u00a0p.I148M variant drives fatty liver disease susceptibility in women","volume":"29","author":"Cherubini","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12876-021-01660-5","article-title":"A\u00a0randomised placebo controlled trial of VSL#3\u00ae probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.pharmr.2024.100018_bib37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","article-title":"Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease","volume":"68","author":"Chu","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2024.100018_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MOG.0b013e32834e7b4b","article-title":"Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression","volume":"28","author":"Corbin","year":"2012","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.pharmr.2024.100018_bib39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nm.3766","article-title":"Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis","volume":"21","author":"Crane","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib40","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pharmr.2024.100018_bib41","article-title":"Toward nanotechnology-enabled application of bilirubin in the treatment and diagnosis of various civilization diseases","volume":"20","author":"Cui","year":"2023","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.pharmr.2024.100018_bib42","doi-asserted-by":"crossref","first-page":"25123","DOI":"10.1074\/jbc.M112.375907","article-title":"Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21","volume":"287","author":"Cyphert","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pharmr.2024.100018_bib43","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.tem.2010.08.010","article-title":"JNK regulation of hepatic manifestations of the metabolic syndrome","volume":"21","author":"Czaja","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2024.100018_bib44","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gutjnl-2014-308778","article-title":"Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology","volume":"65","author":"Dao","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2024.100018_bib45","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1136\/gutjnl-2015-309957","article-title":"High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome","volume":"65","author":"De Filippis","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2024.100018_bib46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41586-021-03671-4","article-title":"Evaluating microbiome\u2013directed fibre snacks in gnotobiotic mice and humans","volume":"595","author":"Delannoy-Bruno","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2024.100018_bib47","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jhep.2021.11.029","article-title":"The fecal mycobiome in non\u2013alcoholic fatty liver disease","volume":"76","author":"Demir","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib48","doi-asserted-by":"crossref","first-page":"G900","DOI":"10.1152\/ajpgi.00265.2013","article-title":"Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids","volume":"305","author":"den Besten","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.pharmr.2024.100018_bib49","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study","volume":"25","author":"Depommier","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib50","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/gutjnl-2012-303304","article-title":"Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women","volume":"62","author":"Dewulf","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2024.100018_bib51","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2024.100018_bib52","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","article-title":"Current therapies and new developments in NASH","volume":"71","author":"Dufour","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2024.100018_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2013.11.001","article-title":"Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease","volume":"146","author":"Dumas","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2024.100018_bib54","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2011.11.062","article-title":"Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones","volume":"148","author":"Dutchak","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pharmr.2024.100018_bib55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology","volume":"17","author":"Eslam","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib56","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib57","doi-asserted-by":"crossref","first-page":"9066","DOI":"10.1073\/pnas.1219451110","article-title":"Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity","volume":"110","author":"Everard","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2024.100018_bib58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2024.100018_bib59","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A\u00a0randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib60","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000335","article-title":"Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis","volume":"8","author":"Francque","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.pharmr.2024.100018_bib61","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2024.100018_bib62","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A\u00a0randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib63","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/db08-1637","article-title":"Butyrate improves insulin sensitivity and increases energy expenditure in mice","volume":"58","author":"Gao","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2024.100018_bib64","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2010.06.021","article-title":"Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C","volume":"54","author":"Garc\u00eda-Monz\u00f3n","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib65","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/advances\/nmx007","article-title":"Practical dietary recommendations for the prevention and management of nonalcoholic fatty liver disease in adults","volume":"9","author":"George","year":"2018","journal-title":"Adv Nutr"},{"key":"10.1016\/j.pharmr.2024.100018_bib66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","article-title":"Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics","volume":"14","author":"Gibson","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib68","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/jhep.2003.50348","article-title":"Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC)","volume":"38","author":"Gilat","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib69","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.dld.2014.02.010","article-title":"Intestinal permeability is increased in children with non\u2013alcoholic fatty liver disease, and correlates with liver disease severity","volume":"46","author":"Giorgio","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.pharmr.2024.100018_bib70","first-page":"100","article-title":"Macrophages in nonalcoholic steatohepatitis: friend or foe?","volume":"6","author":"Grunhut","year":"2018","journal-title":"Eur Med J Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib71","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A\u00a0phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib72","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non\u2013alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib73","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-9255-7-15","article-title":"Elevated endotoxin levels in non-alcoholic fatty liver disease","volume":"7","author":"Harte","year":"2010","journal-title":"J\u00a0Inflamm (Lond)"},{"key":"10.1016\/j.pharmr.2024.100018_bib75","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmr.2024.100018_bib76","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.pharmr.2024.100018_bib77","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the liver\u2013\u2013from homeostasis to disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib78","doi-asserted-by":"crossref","first-page":"25179","DOI":"10.1074\/jbc.M116.731703","article-title":"Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK) 3\u03b2 phosphorylation of serine 73 of peroxisome proliferator-activated receptor (PPAR) \u03b1","volume":"291","author":"Hinds","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pharmr.2024.100018_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.594574","article-title":"Bilirubin nanoparticles reduce diet-induced hepatic steatosis, improve fat utilization, and increase plasma beta-hydroxybutyrate","volume":"11","author":"Hinds","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharmr.2024.100018_bib80","doi-asserted-by":"crossref","first-page":"E244","DOI":"10.1152\/ajpendo.00396.2016","article-title":"Mice with hyperbilirubinemia due to Gilbert's syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPAR\u03b1","volume":"312","author":"Hinds","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2024.100018_bib81","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature01137","article-title":"A\u00a0central role for JNK in obesity and insulin resistance","volume":"420","author":"Hirosumi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2024.100018_bib82","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non\u2013diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib83","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib84","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib85","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","volume":"22","author":"Huby","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmr.2024.100018_bib86","doi-asserted-by":"crossref","first-page":"G1318","DOI":"10.1152\/ajpgi.00405.2005","article-title":"LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice","volume":"290","author":"Isayama","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.pharmr.2024.100018_bib87","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib88","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.3390\/nu11092062","article-title":"Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress","volume":"11","author":"Ji","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmr.2024.100018_bib89","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrgastro.2017.119","article-title":"Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib90","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2024.100018_bib91","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis","volume":"36","author":"Jiao","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.pharmr.2024.100018_bib92","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm.4294","article-title":"An emerging role for neutrophil extracellular traps in noninfectious disease","volume":"23","author":"Jorch","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111321","article-title":"Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice","volume":"40","author":"Kabbani","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.pharmr.2024.100018_bib94","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/ajg.2014.133","article-title":"Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients","volume":"109","author":"Kelly","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pharmr.2024.100018_bib95","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/metabo13020215","article-title":"Bilirubin nanoparticle treatment in obese mice inhibits hepatic ceramide production and remodels liver fat content","volume":"13","author":"Kipp","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.pharmr.2024.100018_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2024.100018_bib97","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/apt.15416","article-title":"Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease","volume":"50","author":"Koopman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2024.100018_bib98","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cmet.2017.09.008","article-title":"Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition","volume":"26","author":"Kootte","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2024.100018_bib99","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmr.2024.100018_bib100","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmr.2024.100018_bib101","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/hep.32197","article-title":"Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease","volume":"75","author":"Kwan","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib102","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","article-title":"Intestinal virome signature associated with severity of nonalcoholic fatty liver disease","volume":"159","author":"Lang","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2024.100018_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104952","article-title":"Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid","volume":"100","author":"Lau","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmr.2024.100018_bib104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/path.4829","article-title":"Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances","volume":"241","author":"Lau","year":"2017","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pharmr.2024.100018_bib105","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2024.100018_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.248","article-title":"ER stress induces NLRP3 inflammasome activation and hepatocyte death","volume":"6","author":"Lebeaupin","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pharmr.2024.100018_bib107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abk0855","article-title":"Risk assessment with gut microbiome and metabolite markers in NAFLD development","volume":"14","author":"Leung","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib108","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1172\/JCI65179","article-title":"Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis","volume":"122","author":"Li","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pharmr.2024.100018_bib109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Lind\u00e9n","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.pharmr.2024.100018_bib110","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1039\/C8FO01143E","article-title":"Deoxycholic acid disrupts the intestinal mucosal barrier and promotes intestinal tumorigenesis","volume":"9","author":"Liu","year":"2018","journal-title":"Food Funct"},{"key":"10.1016\/j.pharmr.2024.100018_bib111","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-016-0307-y","article-title":"The healthy human microbiome","volume":"8","author":"Lloyd-Price","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib112","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/01.mcg.0000165671.25272.0f","article-title":"Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases","volume":"39","author":"Loguercio","year":"2005","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.pharmr.2024.100018_bib113","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-16-0932","article-title":"Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity","volume":"7","author":"Loo","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pharmr.2024.100018_bib114","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.pharmr.2024.100018_bib115","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib116","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2024.100018_bib117","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/21505594.2021.2019950","article-title":"Pathogenesis and virulence of Candida albicans","volume":"13","author":"Lopes","year":"2022","journal-title":"Virulence"},{"key":"10.1016\/j.pharmr.2024.100018_bib118","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jcmgh.2015.01.001","article-title":"Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability","volume":"1","author":"Luther","year":"2015","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib119","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2021.10.013","article-title":"Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease","volume":"76","author":"Luukkonen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib120","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217543120","article-title":"Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis","volume":"120","author":"Luukkonen","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2024.100018_bib121","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132158","article-title":"Hydroxysteroid 17-\u03b2 dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease","volume":"5","author":"Luukkonen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmr.2024.100018_bib122","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pharmr.2024.100018_bib123","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/hep.31115","article-title":"Indole alleviates diet-induced hepatic steatosis and inflammation in a manner involving myeloid cell 6-phosphofructo-2-kinase\/fructose-2,6-biphosphatase 3","volume":"72","author":"Ma","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib124","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/hep.31517","article-title":"17-beta hydroxysteroid dehydrogenase 13 deficiency does not protect mice from obesogenic diet injury","volume":"73","author":"Ma","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib125","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.22399","article-title":"Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis","volume":"48","author":"Maher","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib126","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A\u00a0phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib127","first-page":"339","article-title":"Choline\u2019s role in maintaining liver function: new evidence for epigenetic mechanisms","volume":"16","author":"Mehedint","year":"2013","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.pharmr.2024.100018_bib128","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4161\/gmic.28572","article-title":"Characterization of the 17 strains of regulatory T cell-inducing human-derived Clostridia","volume":"5","author":"Narushima","year":"2014","journal-title":"Gut Microbes"},{"key":"10.1016\/j.pharmr.2024.100018_bib130","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib131","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A\u00a0universal gut-microbiome-derived signature predicts cirrhosis","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2024.100018_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110226","article-title":"Sodium acetate-mediated inhibition of histone deacetylase alleviates hepatic lipid dysregulation and its accompanied injury in streptozotocin\u2013nicotinamide\u2013induced diabetic rats","volume":"128","author":"Olaniyi","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2024.100018_bib133","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/0974-2700.42203","article-title":"Mucormycosis in immunochallenged patients","volume":"1","author":"Pak","year":"2008","journal-title":"J\u00a0Emerg Trauma Shock"},{"key":"10.1016\/j.pharmr.2024.100018_bib134","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41467-022-28044-x","article-title":"The mitochondrial \u03b2-oxidation enzyme HADHA restrains hepatic glucagon response by promoting \u03b2-hydroxybutyrate production","volume":"13","author":"Pan","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2024.100018_bib135","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1172\/JCI86013","article-title":"Insulin receptor Thr1160 phosphorylation mediates lipid\u2013induced hepatic insulin resistance","volume":"126","author":"Petersen","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pharmr.2024.100018_bib136","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tips.2017.04.004","article-title":"Roles of diacylglycerols and ceramides in hepatic insulin resistance","volume":"38","author":"Petersen","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmr.2024.100018_bib137","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nm.4236","article-title":"A\u00a0purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice","volume":"23","author":"Plovier","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib138","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmr.2024.100018_bib139","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib140","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2024.100018_bib141","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2024.100018_bib142","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/gutjnl-2014-307649","article-title":"Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn\u2019s disease","volume":"65","author":"Qu\u00e9vrain","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2024.100018_bib143","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib144","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib145","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1177\/2050640618804444","article-title":"Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease","volume":"6","author":"Rau","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.pharmr.2024.100018_bib146","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.1501175","article-title":"Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver","volume":"196","author":"Rau","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.pharmr.2024.100018_bib147","first-page":"218","article-title":"Resmetirom proves positive for NASH with liver fibrosis","volume":"21","author":"Ray","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib148","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib149","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nature25973","article-title":"Environment dominates over host genetics in shaping human gut microbiota","volume":"555","author":"Rothschild","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2024.100018_bib150","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s11695-007-9243-7","article-title":"Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis","volume":"17","author":"Ruiz","year":"2007","journal-title":"Obes Surg"},{"key":"10.1016\/j.pharmr.2024.100018_bib151","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.mib.2013.07.002","article-title":"Colonic bacterial metabolites and human health","volume":"16","author":"Russell","year":"2013","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.pharmr.2024.100018_bib152","doi-asserted-by":"crossref","first-page":"16767","DOI":"10.1073\/pnas.0808567105","article-title":"Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41","volume":"105","author":"Samuel","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2024.100018_bib153","doi-asserted-by":"crossref","first-page":"32345","DOI":"10.1074\/jbc.M313478200","article-title":"Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease","volume":"279","author":"Samuel","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.pharmr.2024.100018_bib154","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2024.100018_bib155","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib156","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib157","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41419-023-05853-6","article-title":"Butyrate limits inflammatory macrophage niche in NASH","volume":"14","author":"Sarkar","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.pharmr.2024.100018_bib158","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41591-019-0485-4","article-title":"Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism","volume":"25","author":"Scheiman","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib159","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","article-title":"Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease","volume":"157","author":"Schwimmer","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2024.100018_bib160","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib161","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa0708681","article-title":"Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet","volume":"359","author":"Shai","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib162","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chom.2019.01.017","article-title":"Bacteriophages of the human gut: The \u201cKnown Unknown\u201d of the microbiome","volume":"25","author":"Shkoporov","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.pharmr.2024.100018_bib163","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib164","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1186\/s13063-019-3679-7","article-title":"Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol","volume":"20","author":"Silva-Sperb","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.pharmr.2024.100018_bib165","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib166","doi-asserted-by":"crossref","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2024.100018_bib167","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non\u2013alcoholic fatty liver disease\u2013associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib168","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib169","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1055\/s-0039-1679920","article-title":"Genetics of nonalcoholic fatty liver disease: from pathogenesis to therapeutics","volume":"39","author":"Sookoian","year":"2019","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.pharmr.2024.100018_bib170","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2010.11.049","article-title":"Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency","volume":"140","author":"Spencer","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2024.100018_bib171","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jhep.2023.07.004","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"79","author":"Staels","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib172","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153427","article-title":"Bilirubin binding to PPAR\u03b1 inhibits lipid accumulation","volume":"11","author":"Stec","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2024.100018_bib173","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1038\/s41467-022-34299-1","article-title":"Phosphorylation of 17\u03b2-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice","volume":"13","author":"Su","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmr.2024.100018_bib174","doi-asserted-by":"crossref","first-page":"21309","DOI":"10.18632\/aging.203460","article-title":"Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults","volume":"13","author":"Sui","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.pharmr.2024.100018_bib175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","article-title":"Adaptive immunity: an emerging player in the progression of NAFLD","volume":"17","author":"Sutti","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib176","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201900257","article-title":"Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease","volume":"63","author":"Tan","year":"2019","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.pharmr.2024.100018_bib177","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S2468-1253(24)00049-9","article-title":"Resmetirom for NASH: balancing promise and prudence","volume":"9","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib178","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/metabo12121243","article-title":"Trimethylamine N-oxide levels in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Theofilis","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.pharmr.2024.100018_bib179","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41586-023-06388-8","article-title":"From target discovery to clinical drug development with human genetics","volume":"620","author":"Trajanoska","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2024.100018_bib180","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbalip.2009.10.007","article-title":"Fatty liver and lipotoxicity","volume":"1801","author":"Trauner","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmr.2024.100018_bib181","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib182","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3684","article-title":"The mycobiota: interactions between commensal fungi and the host immune system","volume":"14","author":"Underhill","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharmr.2024.100018_bib183","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/hep.22711","article-title":"VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice","volume":"49","author":"Velayudham","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib184","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJMoa2117872","article-title":"Germline mutations in CIDEB and protection against liver disease","volume":"387","author":"Verweij","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib185","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1007\/s10620-012-2112-9","article-title":"Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD)","volume":"57","author":"Volynets","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.pharmr.2024.100018_bib186","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2012.06.031","article-title":"Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome","volume":"143","author":"Vrieze","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmr.2024.100018_bib187","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cgh.2021.01.017","article-title":"On the proposed definition of metabolic-associated fatty liver disease","volume":"19","author":"Wai-Sun Wong","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib188","article-title":"Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2024.100018_bib189","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jcmgh.2021.08.019","article-title":"Activated natural killer cell promotes nonalcoholic steatohepatitis through mediating JAK\/STAT pathway","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib190","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med Res Rev"},{"key":"10.1016\/j.pharmr.2024.100018_bib191","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1021\/pr300337s","article-title":"Urinary metabolite variation is associated with pathological progression of the post-hepatitis B cirrhosis patients","volume":"11","author":"Wang","year":"2012","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.pharmr.2024.100018_bib192","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/hep.30583","article-title":"PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib193","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ebiom.2019.03.070","article-title":"Adjunctive fecal microbiota transplantation in supportive oncology: emerging indications and considerations in immunocompromised patients","volume":"44","author":"Wardill","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmr.2024.100018_bib194","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pharmr.2024.100018_bib195","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/hep4.1665","article-title":"Serum bile acid, vitamin E, and serotonin metabolites are associated with future liver-related events in nonalcoholic fatty liver disease","volume":"5","author":"Wegermann","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.pharmr.2024.100018_bib196","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41564-023-01418-7","article-title":"Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid","volume":"8","author":"Wei","year":"2023","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.pharmr.2024.100018_bib197","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/metabo12030238","article-title":"Emerging role of nuclear receptors for the treatment of NAFLD and NASH","volume":"12","author":"Welch","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.pharmr.2024.100018_bib198","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","article-title":"Noninvasive biomarkers in NAFLD and NASH\u2014current progress and future promise","volume":"15","author":"Wong","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib199","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study","volume":"12","author":"Wong","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib200","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/gt.2010.41","article-title":"PPARgamma is essential for protection against nonalcoholic steatohepatitis","volume":"17","author":"Wu","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.pharmr.2024.100018_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.982222","article-title":"Roles and regulation of histone acetylation in hepatocellular carcinoma","volume":"13","author":"Xia","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.pharmr.2024.100018_bib202","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/ijc.30219","article-title":"Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis","volume":"139","author":"Xie","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pharmr.2024.100018_bib203","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1080\/17474124.2022.2016391","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"15","author":"Yang","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib204","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature11053","article-title":"Human gut microbiome viewed across age and geography","volume":"486","author":"Yatsunenko","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2024.100018_bib205","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2024.100018_bib206","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib207","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib208","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2024.100018_bib209","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/hep.23845","article-title":"Endotoxin accumulation prevents carcinogen\u2013induced apoptosis and promotes liver tumorigenesis in rodents","volume":"52","author":"Yu","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib210","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cmet.2019.08.018","article-title":"Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae","volume":"30","author":"Yuan","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2024.100018_bib211","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/jcmm.14839","article-title":"PNPLA3 I148M mediates the regulatory effect of NF-kB on inflammation in PA-treated HepG2 cells","volume":"24","author":"Yuan","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.pharmr.2024.100018_bib212","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","article-title":"Dietary cholesterol drives fatty liver\u2013associated liver cancer by modulating gut microbiota and metabolites","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.pharmr.2024.100018_bib213","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jhep.2019.03.014","article-title":"Macrophage p38alpha promotes nutritional steatohepatitis through M1 polarization","volume":"71","author":"Zhang","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib214","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jhep.2015.09.005","article-title":"CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy","volume":"64","author":"Zhang","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib215","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jhep.2014.07.006","article-title":"CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis","volume":"61","author":"Zhang","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.pharmr.2024.100018_bib220","article-title":"A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis","author":"Zhang","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2024.100018_bib216","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2024.100018_bib217","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109041","article-title":"Indole supplementation ameliorates MCD-induced NASH in mice","volume":"107","author":"Zhu","year":"2022","journal-title":"J\u00a0Nutr Biochem"},{"key":"10.1016\/j.pharmr.2024.100018_bib218","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmr.2024.100018_bib219","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/gutjnl-2017-313952","article-title":"Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome","volume":"67","author":"Zuo","year":"2018","journal-title":"Gut"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724116183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724116183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:46:57Z","timestamp":1762217217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724116183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":220,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0031699724116183"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2024.100018","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological treatment for metabolic dysfunction\u2013associated steatotic liver disease and related disorders: Current and emerging therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2024.100018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100018"}}